within Pharmacolibrary.Drugs.N_NervousSystem.N06B_PsychostimulantsAgentsUsedForAdhdAndNootropics.N06BX12_Acetylcarnitine;

model Acetylcarnitine
  extends Pharmacolibrary.Drugs.ATC.N.N06BX12;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N06BX12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Acetylcarnitine (acetyl-L-carnitine) is an acetylated form of L-carnitine, a naturally occurring molecule involved in the transport of fatty acids into mitochondria for β-oxidation. It has been studied for its neuroprotective properties and potential therapeutic effects in neurological conditions such as Alzheimer's disease, peripheral neuropathy, and depression. It is used as a dietary supplement and for some clinical indications in several countries, but not broadly approved as a prescription medication for CNS disorders in all regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from published studies in healthy adult male volunteers following intravenous administration.</p><h4>References</h4><ol><li><p>Rebouche, CJ (2004). Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. <i>Annals of the New York Academy of Sciences</i> 1033 30–41. DOI:<a href=\"https://doi.org/10.1196/annals.1320.003\">10.1196/annals.1320.003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15591001/\">https://pubmed.ncbi.nlm.nih.gov/15591001</a></p></li><li><p>Evans, AM, et al., &amp; Nation, RL (2000). Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. <i>Clinical pharmacology and therapeutics</i> 68(3) 238–249. DOI:<a href=\"https://doi.org/10.1067/mcp.2000.108850\">10.1067/mcp.2000.108850</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11014405/\">https://pubmed.ncbi.nlm.nih.gov/11014405</a></p></li><li><p>Pace, S, et al., &amp; Evans, AM (2000). Pharmacokinetics of propionyl-L-carnitine in humans: evidence for saturable tubular reabsorption. <i>British journal of clinical pharmacology</i> 50(5) 441–448. DOI:<a href=\"https://doi.org/10.1046/j.1365-2125.2000.00280.x\">10.1046/j.1365-2125.2000.00280.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11069438/\">https://pubmed.ncbi.nlm.nih.gov/11069438</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Acetylcarnitine;
